OCRX CC—One sell-side analyst asked a surprisingly good question: If the IV formulation of OCR_002 does not work out for the acute HE setting, would OCRX still develop the oral formulation of OCR-002 for the post-discharge market? The answer was yes.
OCRX plans to start a phase-1 trial for the oral formulation in 2H15.
OCRX has enrolled “more than 70” patients in STOP-HE, which means that <160 patients (of the 230 in the upsized trial) are yet to be enrolled; guidance for completion of enrollment is 2H16.
Cash at 3/31/15 was $46.1M. Guidance for 2015 cash burn is $28-32M; since $5.1 was burned during 1Q15 (#msg-111643705), the guidance implies burn for the 9-month period from 4/1/15 to 12/31/15 of about $23-27M, and a 2015 year-end cash balance of $19-23M (assuming no financing and no new sources of revenue).
News 
Market Data 
Discover 
AI
